China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Pilot Plan for Promoting the Research and Application of New Approach Methodologies (the "Pioneer Plan"),…

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

Merck's KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China's Only Approved PD‑1 Perioperative Breast Cancer Therapy
CompanyDrug

Merck’s KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China’s Only Approved PD‑1 Perioperative Breast Cancer Therapy

Novo Nordisk's Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China's Broadest‑Label Long‑Acting Growth Hormone
CompanyDrug

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Novo Nordisk's Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
CompanyDrug

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

NMPA Approves Expanded Indication for Merck's Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China
CompanyDrug

NMPA Approves Expanded Indication for Merck’s Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China

FDA Approves Priovant's LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication
CompanyDrug

FDA Approves Priovant’s LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide
CompanyDrug

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide

Pfizer's Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings
CompanyDrug

Pfizer’s Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Qyuns Therapeutics' Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance
CompanyDrug

Qyuns Therapeutics’ Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) announced an exclusive licensing agreement with Somnivera, Inc., a U.S. biotechnology company, for an investigational clinical‑stage drug candidate targeting sleep disorders. Under the terms, Nhwa grants Somnivera the exclusive rights to develop, manufacture,…

HitGen Co‑Invests in Connexus Therapeutics' Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

HitGen Co‑Invests in Connexus Therapeutics’ Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

Asymchem's Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility
Company

Asymchem’s Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease
CompanyDeals

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Shandong Lukang Wins NMPA Registration for Generic Cefuroxime Sodium for Injection – Entering a RMB 2.6 Billion Chinese Cephalosporin Market
CompanyDrug

Shandong Lukang Wins NMPA Registration for Generic Cefuroxime Sodium for Injection – Entering a RMB 2.6 Billion Chinese Cephalosporin Market

Xunfei Healthcare Establishes Hainan Xunfei Internet Hospital Subsidiary with RMB 10 Million Registered Capital – Extending Digital Healthcare Footprint in Hainan Free Trade Port
CompanyHospital

Xunfei Healthcare Establishes Hainan Xunfei Internet Hospital Subsidiary with RMB 10 Million Registered Capital – Extending Digital Healthcare Footprint in Hainan Free Trade Port

GenFleet's Oral KRAS G12D Inhibitor GFH375 Wins Third NMPA Breakthrough Therapy Designation – Combination with Cetuximab for Pretreated Metastatic Colorectal Cancer
CompanyDrug

GenFleet’s Oral KRAS G12D Inhibitor GFH375 Wins Third NMPA Breakthrough Therapy Designation – Combination with Cetuximab for Pretreated Metastatic Colorectal Cancer

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC
CompanyDeals

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192) announced that it has received a US$600 million upfront payment from AstraZeneca plc (NYSE: AZN), stemming from the global exclusive licensing agreement for…

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China
CompanyDeals

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors
CompanyDeals

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion
CompanyDeals

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion

Sino Biopharmaceutical's CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology
CompanyDeals

Sino Biopharmaceutical’s CTTQ Partners With STADA on Pembrolizumab Biosimilar TQB3570 – Exclusive European License With Options Across Oncology and Immunology

- Advertisement -
Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom
CompanyDeals

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

China's NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products
Policy / Regulatory

China’s NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products

China's National Medical Products Administration (NMPA) released the draft Regulations on the Administration of Radiopharmaceuticals and opened a public comment period through October 20. The draft establishes a dedicated regulatory…

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter "Care Program – Extension" While GH56 Advances Pediatric Development
Policy / Regulatory

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter “Care Program – Extension” While GH56 Advances Pediatric Development

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
Policy / Regulatory

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented
Policy / Regulatory

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

More News

NMPA Approves Lilly's Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China
CompanyDrug

NMPA Approves Lilly’s Jaypirca (Pirtobrutinib) as First‑Line Monotherapy for CLL/SLL – Non‑Covalent BTK Inhibitor Completes Line‑of‑Therapy Progression in China

Sinovac and Egypt's GENNVAX Launch sIPV Technical Cooperation Project in Beijing – Sabin Inactivated Polio Vaccine Localization Deal Enters Implementation Phase
CompanyDeals

Sinovac and Egypt’s GENNVAX Launch sIPV Technical Cooperation Project in Beijing – Sabin Inactivated Polio Vaccine Localization Deal Enters Implementation Phase

Merck Licenses SciBrunch's Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal
CompanyDeals

Merck Licenses SciBrunch’s Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

FDA Approves Eli Lilly's Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata
CompanyDrug

FDA Approves Eli Lilly’s Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

FDA Approves Eli Lilly's Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes
CompanyDrug

FDA Approves Eli Lilly’s Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes

AstraZeneca to Invest USD 2 Billion in Summit Therapeutics – Clinical Collaboration Anchored on Ivonescimab and Claudin 18.2 ADC Sone‑Ve
CompanyDeals

AstraZeneca to Invest USD 2 Billion in Summit Therapeutics – Clinical Collaboration Anchored on Ivonescimab and Claudin 18.2 ADC Sone‑Ve

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure
CompanyDrug

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis
CompanyDrug

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

Show More